Presentation is loading. Please wait.

Presentation is loading. Please wait.

Unusual Chemosensitivity of Advanced Bronchioalveolar Carcinoma after Gefitinib Response and Progression: A Case Report  Rafal Dziadziuszko, MD, PhD,

Similar presentations


Presentation on theme: "Unusual Chemosensitivity of Advanced Bronchioalveolar Carcinoma after Gefitinib Response and Progression: A Case Report  Rafal Dziadziuszko, MD, PhD,"— Presentation transcript:

1 Unusual Chemosensitivity of Advanced Bronchioalveolar Carcinoma after Gefitinib Response and Progression: A Case Report  Rafal Dziadziuszko, MD, PhD, Anna Siemiątkowska, MSc, Janusz Limon, MD, PhD, Witold Rzyman, MD, PhD, Jacek Jassem, MD, PhD, Paul A. Bunn, MD, Marileila Varella-Garcia, PhD, Fred R. Hirsch, MD, PhD  Journal of Thoracic Oncology  Volume 2, Issue 1, Pages (January 2007) DOI: /S (15) Copyright © 2007 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 Microscopic and molecular characteristics of the primary tumor. Nonmucinous bronchioalveolar carcinoma (A) (x200) with strong epidermal growth factor receptor (EGFR) protein expression (B) (DAKO Pharm Dx staining kit, x200), EGFR gene amplification (C) (hybridization with the LSI EGFR SpectrumOrange/CEP SpectrumGreen Probe, Vysis, Abbott Molecular), high HER2 gene copy number (D) (hybridization with the PathVysion HER-2 DNA Probe Kit, Vysis, Abbott Molecular) and EGFR exon 19 E746_A750 deletion (E) (sequencing analyzed in Genetic Analyzer ABI PRISM 310). Journal of Thoracic Oncology 2007 2, 91-92DOI: ( /S (15) ) Copyright © 2007 International Association for the Study of Lung Cancer Terms and Conditions


Download ppt "Unusual Chemosensitivity of Advanced Bronchioalveolar Carcinoma after Gefitinib Response and Progression: A Case Report  Rafal Dziadziuszko, MD, PhD,"

Similar presentations


Ads by Google